Literature DB >> 12764515

Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial.

M L A Ferrari1, P M Z Coelho, C M F Antunes, C A P Tavares, A S da Cunha.   

Abstract

OBJECTIVE: To evaluate the therapeutic efficacy of oxamniquine and praziquantel, the two most clinically important schistosomicide drugs, and to compare the accuracy of faecal examination with the accuracy of oogram in testing for Schistosoma mansoni infection.
METHODS: In a triple-masked and randomized controlled trial, 106 patients infected with S. mansoni were randomly allocated to one of three statistically homogeneous groups. One group was given 60 mg/kg praziquantel per day for three consecutive days, another was given two daily doses of 10 mg/kg oxamniquine, and the placebo group received starch. Faecal examinations (days 15, 30, 60, 90, 120, 150, and 180 after treatment) and biopsy of rectal mucosa by quantitative oogram (days 30, 60, 120, and 180) were used for the initial diagnosis and for evaluating the degree of cure. The chi2 test and the Kruskal-Wallis test were used to compare variables in the three groups. Survival analysis (Kaplan-Meier) and the log-rank test were used to evaluate the efficacy of the treatments.
FINDINGS: The sensitivity of stool examinations ranged from 88.9% to 94.4% when patients presented with >5000 S. mansoni eggs per gram of tissue (oogram); when the number of eggs dropped to <1000 eggs per gram, sensitivity was reduced (range, 22.7-34.0%). When cure was evaluated by stool examination, oxamniquine and praziquantel had cure rates of 90.3% and 100%, respectively. However, when the oogram was used as an indicator of sensitivity, the oxamniquine cure rate dropped dramatically (to 42.4%), whereas the rate for praziquantel remained high, at 96.1%.
CONCLUSIONS: Praziquantel was significantly more effective than oxamniquine in treating S. mansoni infection. The oogram was markedly more sensitive than stool examinations in detecting S. mansoni eggs and should be recommended for use in clinical trials with schistosomicides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764515      PMCID: PMC2572425     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  20 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

Review 2.  Species-specific treatment effects of helminth/HIV-1 co-infection: a systematic review and meta-analysis.

Authors:  Laura R Sangaré; Bradley R Herrin; Bradely R Herrin; Grace John-Stewart; Judd L Walson
Journal:  Parasitology       Date:  2011-05-18       Impact factor: 3.234

Review 3.  Neuroparasitic infections: cestodes, trematodes, and protozoans.

Authors:  M D Walker; J R Zunt
Journal:  Semin Neurol       Date:  2005-09       Impact factor: 3.420

Review 4.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

Review 5.  Parasitic central nervous system infections in immunocompromised hosts.

Authors:  Melanie Walker; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-03-02       Impact factor: 9.079

6.  Reduced transmission of human schistosomiasis after restoration of a native river prawn that preys on the snail intermediate host.

Authors:  Susanne H Sokolow; Elizabeth Huttinger; Nicolas Jouanard; Michael H Hsieh; Kevin D Lafferty; Armand M Kuris; Gilles Riveau; Simon Senghor; Cheikh Thiam; Alassane N'Diaye; Djibril Sarr Faye; Giulio A De Leo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

7.  The prophylactic and anti-fibrotic activity of phthalimido-thiazole derivatives in schistosomiasis mansoni.

Authors:  Carlos André Laranjeira Miranda Filho; Míria de Oliveira Barbosa; Arsênio Rodrigues Oliveira; Aline Ferreira Pinto; Daniel Lopes Araújo; Jéssica Paula Lucena; Roni Evêncio de Araújo; Sheilla Andrade de Oliveira; Ana Cristina Lima Leite
Journal:  Parasitol Res       Date:  2022-05-23       Impact factor: 2.289

Review 8.  Spinal cord schistosomiasis.

Authors:  Ahmed Awad Adeel
Journal:  Sudan J Paediatr       Date:  2015

9.  Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni.

Authors:  P Martins-Leite; G Gazzinelli; L F Alves-Oliveira; A Gazzinelli; L C C Malaquias; R Correa-Oliveira; A Teixeira-Carvalho; A M S Silveira
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

10.  A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil.

Authors:  Piero L Olliaro; Michel T Vaillant; Vincente J Belizario; Nicholas J S Lwambo; Mohamed Ouldabdallahi; Otavio S Pieri; Maria L Amarillo; Godfrey M Kaatano; Mamadou Diaw; Analucia C Domingues; Tereza C Favre; Olivier Lapujade; Fabiana Alves; Lester Chitsulo
Journal:  PLoS Negl Trop Dis       Date:  2011-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.